PT  - JOURNAL ARTICLE
AU  - Carolina Cubillos-Zapata
AU  - Miguel Ángel Martínez-García
AU  - Francisco Campos-Rodríguez
AU  - Manuel Sánchez de la Torre
AU  - Eduardo Nagore
AU  - Antonio Martorell-Calatayud
AU  - Luis Hernández Blasco
AU  - Eusebi Chiner Vives
AU  - Jorge Abad-Capa
AU  - Josep María Montserrat
AU  - Valentín Cabriada-Nuño
AU  - Irene Cano-Pumarega
AU  - Jaime Corral-Peñafiel
AU  - Trinidad Diaz-Cambriles
AU  - Olga Mediano
AU  - María Somoza-González
AU  - Joan Dalmau-Arias
AU  - Isaac Almendros
AU  - Ramón Farré
AU  - Eduardo López-Collazo
AU  - David Gozal
AU  - Francisco García-Río
ED  - ,
TI  - Soluble PD-L1 is a potential biomarker of cutaneous melanoma aggressiveness and metastasis in obstructive sleep apnea patients
AID  - 10.1183/13993003.01298-2018
DP  - 2018 Jan 01
TA  - European Respiratory Journal
PG  - 1801298
4099  - http://erj.ersjournals.com/content/early/2018/11/01/13993003.01298-2018.short
4100  - http://erj.ersjournals.com/content/early/2018/11/01/13993003.01298-2018.full
AB  - Obstructive sleep apnea (OSA) up-regulates the programmed cell death-1 receptor and its ligand (PD-L1) pathway, potentially compromising immunosurveillance. We compared circulating levels of soluble PD-L1 (sPD-L1) in patients with cutaneous melanoma (CM) according to the presence and severity of OSA, and evaluated relationships with tumour aggressiveness and invasiveness.In a multicenter observational study, 360 patients with CM underwent sleep studies, and serum sPD-L1 levels were assayed by ELISA. CM aggressiveness indices included mitotic rate, Breslow index, tumour ulceration, Clark level and tumour stage, and sentinel lymph node (SLN) metastasis was recorded as a marker of invasiveness.sPD-L1 levels were higher in severe OSA compared to mild OSA or non-OSA patients. In OSA patients, sPD-L1 levels correlated with Breslow index and were higher in patients with tumour ulceration, advanced primary tumour stages or with loco-regional disease. The incorporation of sPD-L1 to the classic risk factors to SLN metastasis led to net improvements in the classification of 27.3%.Thus, sPD-L1 levels are increased in melanoma patients with severe OSA and, in addition, might serve as a potential biomarker of CM aggressiveness and invasiveness in this group of subjects.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Cubillos-Zapata has nothing to disclose.Conflict of interest: Martínez-García has nothing to disclose.Conflict of interest: Campos-Rodríguez has nothing to disclose.Conflict of interest: de la Torre has nothing to disclose.Conflict of interest: Nagore has nothing to disclose.Conflict of interest: Martorell-Calatayud has nothing to disclose.Conflict of interest: Blasco has nothing to disclose.Conflict of interest: Vives has nothing to disclose.Conflict of interest: Abad-Capa has nothing to disclose.Conflict of interest: Montserrat has nothing to disclose.Conflict of interest: Cabriada-Nuño has nothing to disclose.Conflict of interest: Cano-Pumarega has nothing to disclose.Conflict of interest: Corral-Peñafiel has nothing to disclose.Conflict of interest: Diaz-Cambriles has nothing to disclose.Conflict of interest: Mediano has nothing to disclose.Conflict of interest: Somoza-González has nothing to disclose.Conflict of interest: Dalmau-Arias has nothing to disclose.Conflict of interest: Almendros has nothing to disclose.Conflict of interest: Farré has nothing to disclose.Conflict of interest: López-Collazo has nothing to disclose.Conflict of interest: Gozal has nothing to disclose.Conflict of interest: García-Río has nothing to disclose.